A significant and growing number of commercially insured members have one or more chronic medical conditions that require multiple interactions with the healthcare system in a given year. And there has been a growth in the out-of-pocket costs associated with healthcare services. This analysis identifies tactics plan administrators could adopt that would reduce out-of-pocket costs for brand-name drugs.

This report was commissioned by Eli Lilly.